Literature DB >> 1392620

Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects.

R C Ragin1, P K Donahoe, M K Kenneally, M F Ahmad, D T MacLaughlin.   

Abstract

Separation of copurifying protease activity from recombinant human Müllerian inhibiting substance (rhMIS) bound to a monoclonal antibody immunoaffinity column by a high-salt wash results in cleaner preparations of rhMIS resistant to cleavage upon storage. In addition, an inhibitor of rhMIS antiproliferative activity is removed. Proteolytic cleavages produced by either a copurifying protease or exogenous plasmin occur at residues 229 and 427 but do not abolish rhMIS biological activity. This report details the modified immunoaffinity column isolation protocol suitable for proteins such as rhMIS and describes the biochemical and antiproliferative properties of this protein.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1392620     DOI： 10.1016/1046-5928(92)90020-w

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN： 1046-5928            Impact factor:   1.650


  23 in total

1.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Authors:  Katia Meirelles; Leo Andrew Benedict; David Dombkowski; David Pepin; Frederic I Preffer; Jose Teixeira; Pradeep Singh Tanwar; Robert H Young; David T MacLaughlin; Patricia K Donahoe; Xiaolong Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

2.  Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Authors:  Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

3.  Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

Authors:  E Basal; T Ayeni; Q Zhang; C Langstraat; P K Donahoe; D Pepin; X Yin; E Leof; W Cliby
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

4.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

6.  AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.

Authors:  Motohiro Kano; Amanda E Sosulski; LiHua Zhang; Hatice D Saatcioglu; Dan Wang; Nicholas Nagykery; Mary E Sabatini; Guangping Gao; Patricia K Donahoe; David Pépin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

7.  AMH induces mesonephric cell migration in XX gonads.

Authors:  Andrea J Ross; Christopher Tilman; Humphrey Yao; David MacLaughlin; Blanche Capel
Journal:  Mol Cell Endocrinol       Date:  2003-12-15       Impact factor: 4.102

8.  Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression.

Authors:  Joo Hyun Park; Yoshihiro Tanaka; Nelson A Arango; Lihua Zhang; L Andrew Benedict; Mi In Roh; Patricia K Donahoe; Jose M Teixeira
Journal:  Dev Biol       Date:  2013-12-19       Impact factor: 3.582

9.  SRY recognizes conserved DNA sites in sex-specific promoters.

Authors:  C M Haqq; C Y King; P K Donahoe; M A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

Authors:  Thanos D Papakostas; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Aristomenis Thanos; George Trichonas; Xanthi Koufomichali; Kosisochukwu Anago; Patricia K Donahoe; Jose Teixeira; David T MacLaughlin; Demetrios Vavvas
Journal:  Protein Expr Purif       Date:  2009-09-13       Impact factor: 1.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.